Cogent trial shows lack of adverse interaction between clopidogr...

Courtesy EurekAlert! - Medicine and Health  Wed, 09/23/2009 - 22:00

(Cardiovascular Research Foundation) Results from a late breaking clinical trial called COGENT demonstrate that the combination of giving patients clopidogrel, a blood thinner commonly prescribed to patients with cardiovascular disease, and stomach medicines such as omeprazole, known as proton pump inhibitors, did not lead to adverse events, as some prior studies had suggested.

The results were presented at the 21st annual Transcatheter Cardiovascular Therapeutics scientific symposium, sponsored by the Cardiovascular Research Foundation.

Tags:

 

More related items

FDA Issues Warning on Acid Reflux Drugs
(MedPage Today) -- The FDA warned today that use of proton pump inhibitors -- including popular brands such as Nexium, Prilosec, and Prevacid -- may increase the risk of Clostridium...

Global conference on stem cell therapy for heart...
(Cardiovascular Research Foundation) The Seventh International Conference on Cell Therapy for Cardiovascular Disease sponsored by the Cardiovascular Research Foundation is a comprehensive...

CRP Has Edge in Predicting PCI Outcome (CME/CE)
(MedPage Today) -- Compared with platelet reactivity to clopidogrel (Plavix), the measure of C-reactive protein (CRP) was a better predictor of adverse cardiovascular events in patients...

Burt's Bees - Baby Bee Buttermilk Lotion, 7 fl oz...
Baby Bee Buttermilk Lotion contains only Mother Nature's safe and gentle ingredients, and is enriched with vitamin E, Aloe Vera and Buttermilk to provide soothing and nourishing emollients...

ghd MK4 Professional Advanced Ceramic Heat-Styler, 1"
Endorsed by the world's top session stylists and hottest celebrities, the revolutionary, professional ghd MK4 original ceramic styling iron is everybody's number one must-have beauty...


 

Post new comment

The content of this field is kept private and will not be shown publicly.
health-fitness.marc8.com